Silence Therapeutics Plc American Depository Share Share Price
NASDAQ: SLN | Small CapSilence Therapeutics Plc American Depository Share Stock Performance
Open $13.47 | Prev. Close $13.46 | Circuit Range N/A |
Day Range $13.18 - $13.68 | Year Range $4.20 - $17.51 | Volume 51,414 |
Average Traded $13.40 |
Silence Therapeutics Plc American Depository Share Share Price Today
As of 30 August 2026, Silence Therapeutics Plc American Depository Share's share price is $13.46. The stock opened at $13.47, compared to its previous close of $13.46. During today's trading session, Silence Therapeutics Plc American Depository Share's share price traded between $13.18 and $13.68, with an average price of $13.43. Over the past 52 weeks, the stock has recorded a high of $17.51 and a low of $4.20. In terms of performance, Silence Therapeutics Plc American Depository Share's share price has risen by 145.62% over the last six months and is up 178.96% on a year-on-year basis.
Silence Therapeutics Plc American Depository Share Share Price Chart
Silence Therapeutics Plc American Depository Share Stock Fundamentals & Key Indicators
Market Cap $1.91B | PE Ratio (TTM) -21.37 | Dividend Yield N/A |
EPS (TTM) $-0.63 | Revenue (TTM) $559000.00 | Return On Equity (TTM) -142.23% |
Profit Margin -15851.88% | Debt to Equity 0.22 | Quarterly Earnings Growth YoY N/A |
Silence Therapeutics Plc American Depository Share Quarterly Profit & Loss
All figures in USD
Silence Therapeutics Plc American Depository Share Annual Profit & Loss
All figures in USD
About Silence Therapeutics Plc American Depository Share
Silence Therapeutics plc, a biotechnology company, engages in the discovery and development of novel molecules incorporating short interfering ribonucleic acid (siRNA) to inhibit the expression of specific target genes in hematology, cardiovascular, and rare diseases. The company develops Zerlasiran (SLN360), which is in Phase II clinical trial for cardiovascular disease associated with elevated lipoprotein(a); Divesiran (SLN124), an siRNA molecule that is in Phase I clinical trial for the treatment of genetic hematological conditions, including polycythemia vera; and SLN548 for complement-mediated disease. Silence Therapeutics plc has collaboration agreements with AstraZeneca PLC to discover, develop, and commercialize siRNA therapeutics for the treatment of cardiovascular, renal, metabolic, and respiratory diseases; and Hansoh Pharmaceutical Group Company Limited to develop siRNAs. The company was formerly known as SR Pharma plc and changed its name to Silence Therapeutics plc in May 2007. Silence Therapeutics plc was incorporated in 1994 and is headquartered in London, the United Kingdom.
Silence Therapeutics Plc American Depository Share Historical Returns
| Month | Open | Close | Change % |
|---|---|---|---|
Aug 2026 | $10.43 | $13.44 | +28.37% |
Jul 2026 | $11.05 | $10.47 | -4.73% |
Jun 2026 | $6.76 | $10.99 | +59.04% |
May 2026 | $7.08 | $6.91 | -5.60% |
Apr 2026 | $5.86 | $7.32 | +39.69% |
Mar 2026 | $5.51 | $5.24 | -4.38% |
Feb 2026 | $4.83 | $5.48 | +13.81% |
Jan 2026 | $6.14 | $4.82 | -20.81% |
Dec 2025 | $6.68 | $6.08 | -9.25% |
Nov 2025 | $7.24 | $6.70 | -6.10% |
Oct 2025 | $5.25 | $7.13 | +40.18% |
Sep 2025 | $4.80 | $5.09 | +5.49% |
SLN Share Price FAQs
What is Silence Therapeutics Plc American Depository Share share price today?
What is the 52 week high and 52 week low of Silence Therapeutics Plc American Depository Share stock?
What is SLN's market capitalisation today?
What is SLN's net income for the last quarter?
What is the 5 year returns of SLN?
What is the high & low stock price of SLN today?
Can I buy SLN shares in India?